ARGX Stock Summary and Trading Ideas (Argenx Se - American Depositary Shares | NASDAQ:ARGX)

Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.

Argenx Se - American Depositary Shares trades on the NASDAQ stock market under the symbol ARGX.

As of April 15, 2024, ARGX stock price declined to $376.26 with 187,483 million shares trading.

ARGX has a beta of 0.89, meaning it tends to be less sensitive to market movements. ARGX has a correlation of 0.04 to the broad based SPY ETF.

ARGX has a market cap of $22.31 billion. This is considered a Large Cap stock.

In the last 3 years, ARGX stock traded as high as $550.76 and as low as $248.21.

The top ETF exchange traded funds that ARGX belongs to (by Net Assets): IBB, FBT, BBH, QQQJ, TCAF.

ARGX has underperformed the market in the last year with a price return of -0.9% while the SPY ETF gained +25.3%. ARGX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +0.7% and -4.4%, respectively, while the SPY returned +6.2% and -3.6%, respectively.

ARGX support price is $371.27 and resistance is $384.77 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARGX stock will trade within this expected range on the day.